Van ECK Associates Corp Has $58.38 Million Position in Vertex Pharmaceuticals Incorporated $VRTX

Key Points

• Van ECK Associates Corp raised its stake in Vertex to 149,056 shares (a 5.9% increase), representing approximately $58.38 million and about 0.06% of the company at quarter‑end.
• Positive interim results from the RAINIER Phase‑3 trial for povetacicept drove the stock higher (stock up 8.3%), spurred multiple analyst price‑target upgrades and left the consensus rating as a "Moderate Buy" with a $551.77 target.
• Vertex reported $5.03 EPS (missed estimates by $0.02) and $3.19 billion in revenue (up 9.5% YoY) for the quarter, with analysts forecasting $15.63 EPS for the current fiscal year.

Van ECK Associates Corp raised its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 5.9% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 149,056 shares of the pharmaceutical company's stock after acquiring an additional 8,355 shares during the period. Van ECK Associates Corp owned approximately 0.06% of Vertex Pharmaceuticals worth $58,376,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the company. Chesapeake Asset Management LLC boosted its stake in Vertex Pharmaceuticals by 110.0% in the third quarter. Chesapeake Asset Management LLC now owns 63 shares of the pharmaceutical company's stock valued at $25,000 after buying an additional 33 shares in the last quarter. Colonial Trust Co SC boosted its stake in shares of Vertex Pharmaceuticals by 118.8% in the 3rd quarter. Colonial Trust Co SC now owns 70 shares of the pharmaceutical company's stock valued at $27,000 after purchasing an additional 38 shares in the last quarter. Total Investment Management Inc. bought a new stake in shares of Vertex Pharmaceuticals during the 2nd quarter valued at approximately $33,000. Financial Network Wealth Advisors LLC increased its position in Vertex Pharmaceuticals by 50.9% during the 3rd quarter. Financial Network Wealth Advisors LLC now owns 86 shares of the pharmaceutical company's stock worth $34,000 after purchasing an additional 29 shares in the last quarter. Finally, Y.D. More Investments Ltd lifted its stake in Vertex Pharmaceuticals by 345.0% in the 3rd quarter. Y.D. More Investments Ltd now owns 89 shares of the pharmaceutical company's stock valued at $35,000 after purchasing an additional 69 shares during the last quarter. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Vertex Pharmaceuticals Stock Up 8.3%

NASDAQ VRTX opened at $499.17 on Wednesday. The company has a market capitalization of $126.80 billion, a price-to-earnings ratio of 32.56 and a beta of 0.31. Vertex Pharmaceuticals Incorporated has a twelve month low of $362.50 and a twelve month high of $519.68. The stock has a fifty day simple moving average of $468.41 and a 200 day simple moving average of $436.53.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last released its quarterly earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 EPS for the quarter, missing analysts' consensus estimates of $5.05 by ($0.02). The company had revenue of $3.19 billion during the quarter, compared to the consensus estimate of $3.18 billion. Vertex Pharmaceuticals had a net margin of 32.94% and a return on equity of 24.30%. The company's quarterly revenue was up 9.5% on a year-over-year basis. During the same quarter last year, the firm posted $3.98 EPS. Research analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

VRTX has been the topic of a number of research reports. Oppenheimer boosted their target price on shares of Vertex Pharmaceuticals from $540.00 to $600.00 and gave the stock an "outperform" rating in a research note on Tuesday. UBS Group raised their price objective on Vertex Pharmaceuticals from $535.00 to $545.00 and gave the company a "buy" rating in a report on Monday, January 26th. Bank of America boosted their price objective on Vertex Pharmaceuticals from $571.00 to $598.00 and gave the stock a "buy" rating in a research report on Tuesday. Weiss Ratings upgraded Vertex Pharmaceuticals from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Wednesday, February 4th. Finally, Leerink Partners lifted their price target on Vertex Pharmaceuticals from $456.00 to $525.00 and gave the company an "outperform" rating in a research note on Monday, December 29th. Twenty-three equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company's stock. According to MarketBeat.com, Vertex Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $551.77.

More Vertex Pharmaceuticals News

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: RAINIER interim analysis met its primary and all secondary endpoints; povetacicept produced large reductions in proteinuria (reported ~52% reduction in interim data), supporting Vertex’s plan to pursue regulatory filings. Vertex Announces Positive Week 36 Interim Analysis Results (BusinessWire)
• Positive Sentiment: News outlets report the trial outcome as “remarkable,” driving strong upside in the stock as investors price in best‑in‑class potential and faster approval expectations. Investopedia coverage
• Positive Sentiment: Multiple brokerages raised ratings/price targets or initiated coverage after the data (examples cited include Morgan Stanley, BofA, Oppenheimer, HC Wainwright, Citigroup, Jefferies), signaling upgraded revenue forecasts and increased upside. Brokerage price‑target and coverage updates (Benzinga roundup)
• Positive Sentiment: Market commentary and midday movers lists confirm the stock’s leadership on the day as headlines on the kidney drug drove volume and momentum. CNBC movers
• Neutral Sentiment: Coverage notes that Vertex’s acquisition of the asset and pipeline expansion into nephrology underpins long‑term upside, but these remain dependent on full data, pricing, and reimbursement. BMO coverage (Globe & Mail)
• Neutral Sentiment: Broader market/technical context: commentary that biotech weighting in Nasdaq indexes is rising may provide additional demand/support for VRTX, but index flows are secondary to clinical and regulatory milestones. Kalkine Media on Nasdaq biotech focus
• Neutral Sentiment: Investor events/transcripts (Leerink presentation) available — useful for management commentary but not immediate catalysts versus the RAINIER news. Leerink conference transcript (Seeking Alpha)

Insiders Place Their Bets

In other news, EVP Ourania Tatsis sold 260 shares of the business's stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $486.35, for a total value of $126,451.00. Following the transaction, the executive vice president owned 46,763 shares in the company, valued at approximately $22,743,185.05. The trade was a 0.55% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Jonathan Biller sold 945 shares of the company's stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $486.35, for a total transaction of $459,600.75. Following the completion of the sale, the executive vice president directly owned 13,659 shares in the company, valued at approximately $6,643,054.65. This represents a 6.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 91,156 shares of company stock valued at $42,845,497 over the last three months. Insiders own 0.20% of the company's stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex's marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.